Loading...
XHKG
2197
Market cap78mUSD
Jul 18, Last price  
0.48HKD
1D
-1.04%
1Q
142.35%
IPO
-94.84%
Name

Clover Biopharmaceuticals Ltd

Chart & Performance

D1W1MN
P/E
P/S
14.67
EPS
Div Yield, %
Shrs. gr., 5y
1.60%
Rev. gr., 5y
%
Revenues
38m
-2.13%
000039,255,00038,419,000
Net income
-903m
L+552.11%
-58,915,000-915,871,000-6,017,915,000-2,451,674,000-138,539,000-903,428,000
CFO
0k
P
-26,617,000476,927,000-917,749,000-1,690,809,000-727,878,0000

Profile

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.
IPO date
Nov 05, 2021
Employees
681
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
38,419
-2.13%
39,255
 
Cost of revenue
989,626
772,139
2,054,037
Unusual Expense (Income)
NOPBT
(951,207)
(732,884)
(2,054,037)
NOPBT Margin
Operating Taxes
(229)
Tax Rate
NOPAT
(951,207)
(732,884)
(2,053,808)
Net income
(903,428)
552.11%
(138,539)
-94.35%
(2,451,674)
-59.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
84
453,155
BB yield
-0.01%
-15.88%
Debt
Debt current
86,149
326,598
317,630
Long-term debt
19,173
34,241
97,046
Deferred revenue
2,496,900
Other long-term liabilities
537,884
549,411
2,496,900
Net debt
(322,205)
(392,133)
(1,225,905)
Cash flow
Cash from operating activities
(727,878)
(1,690,809)
CAPEX
(6,952)
(105,560)
Cash from investing activities
(6,161)
(37,506)
Cash from financing activities
(142,408)
483,143
FCF
205,154
(351,304)
(2,236,723)
Balance
Cash
427,527
752,972
1,640,581
Long term investments
Excess cash
425,606
751,009
1,640,581
Stockholders' equity
(1,636,272)
(9,639,430)
(9,230,511)
Invested Capital
627,502
9,790,459
13,904,258
ROIC
ROCE
94.29%
EV
Common stock shares outstanding
1,253,673
1,243,504
1,102,104
Price
0.24
-61.13%
0.62
-76.06%
2.59
-80.81%
Market cap
302,135
-60.81%
770,973
-72.99%
2,854,448
-54.25%
EV
(20,070)
378,840
1,628,543
EBITDA
(951,207)
(658,142)
(1,993,943)
EV/EBITDA
0.02
Interest
18,723
5,930
Interest/NOPBT